### Learner Notification

**MED Learning Group**

**The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age-Related Macular Degeneration in an Era of Expanded Treatment Options – AMD Virtual Pathways Activity**

**August 31, 2023 – August 31, 2024**

**Online**

**Acknowledgement of Financial Commercial Support**

Regeneron Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 0.50 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Evaluate technological advancements to incorporate into best practices for timely diagnosis and/or effective interval monitoring of DME and nAMD.
2. Discuss the benefits and treatment burdens of conventional anti-VEGF therapies for patients with retinal vascular disease.
3. Compare the safety, efficacy and durability of established and emerging therapies for patients with nAMD and DME.
4. Personalize treatment and dosing strategies for patients with DME or nAMD based patient-, disease-, and treatment-related factors.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Ana Maria | Albino | NA |
| Daniel | DaSilva | NA |
| Jessica | Feygin | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Nicole | Longo | NA |
| Juan Carlos | Martinez Camarillo | Lutronic Vision: Contracted Research, Patent Holder |
| Chimene | Richa | NA |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)